Literature DB >> 24895056

Targeted delivery of miRNA therapeutics for cardiovascular diseases: opportunities and challenges.

Rick F J Kwekkeboom1, Zhiyong Lei2, Pieter A Doevendans, René J P Musters1, Joost P G Sluijter.   

Abstract

Dysregulation of miRNA expression has been associated with many cardiovascular diseases in animal models, as well as in patients. In the present review, we summarize recent findings on the role of miRNAs in cardiovascular diseases and discuss the opportunities, possibilities and challenges of using miRNAs as future therapeutic targets. Furthermore, we focus on the different approaches that can be used to deliver these newly developed miRNA therapeutics to their sites of action. Since siRNAs are structurally homologous with the miRNA therapeutics, important lessons learned from siRNA delivery strategies are discussed that might be applicable to targeted delivery of miRNA therapeutics, thereby reducing costs and potential side effects, and improving efficacy.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24895056     DOI： 10.1042/CS20140005

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN： 0143-5221            Impact factor:   6.124


  24 in total

Review 1.  RNA interference-based therapy and its delivery systems.

Authors:  Xiuhui Chen; Lingegowda S Mangala; Cristian Rodriguez-Aguayo; Xianchao Kong; Gabriel Lopez-Berestein; Anil K Sood
Journal:  Cancer Metastasis Rev       Date:  2018-03       Impact factor: 9.264

2.  Effects of duloxetine on microRNA expression profile in frontal lobe and hippocampus in a mouse model of depression.

Authors:  Bing Pan; Yamei Liu
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

3.  Heart Failure in Chronic Myocarditis: A Role for microRNAs?

Authors:  P van den Hoogen; F van den Akker; J C Deddens; J P G Sluijter
Journal:  Curr Genomics       Date:  2015-04       Impact factor: 2.236

4.  MicroRNA-132/212 family enhances arteriogenesis after hindlimb ischaemia through modulation of the Ras-MAPK pathway.

Authors:  Zhiyong Lei; Alain van Mil; Maarten M Brandt; Sebastian Grundmann; Imo Hoefer; Michiel Smits; Hamid El Azzouzi; Taro Fukao; Caroline Cheng; Pieter A Doevendans; Joost P G Sluijter
Journal:  J Cell Mol Med       Date:  2015-05-06       Impact factor: 5.310

5.  Rule discovery and distance separation to detect reliable miRNA biomarkers for the diagnosis of lung squamous cell carcinoma.

Authors:  Renhua Song; Qian Liu; Gyorgy Hutvagner; Hung Nguyen; Kotagiri Ramamohanarao; Limsoon Wong; Jinyan Li
Journal:  BMC Genomics       Date:  2014-12-08       Impact factor: 3.969

6.  A snapshot of genetic and epigenetic basis of arrhythmia and heart failure.

Authors:  Junjie Xiao; Joost P G Sluijter; Saumya Das; Yiqing Yang; Zhongming Shen
Journal:  Front Genet       Date:  2015-03-03       Impact factor: 4.599

Review 7.  MicroRNA and Heart Failure.

Authors:  Lee Lee Wong; Juan Wang; Oi Wah Liew; Arthur Mark Richards; Yei-Tsung Chen
Journal:  Int J Mol Sci       Date:  2016-04-06       Impact factor: 5.923

Review 8.  Targeting oncomiRNAs and mimicking tumor suppressor miRNAs: Νew trends in the development of miRNA therapeutic strategies in oncology (Review).

Authors:  Roberto Gambari; Eleonora Brognara; Demetrios A Spandidos; Enrica Fabbri
Journal:  Int J Oncol       Date:  2016-05-04       Impact factor: 5.650

Review 9.  MicroRNA Targeting to Modulate Tumor Microenvironment.

Authors:  Praneeth R Kuninty; Jonas Schnittert; Gert Storm; Jai Prakash
Journal:  Front Oncol       Date:  2016-01-19       Impact factor: 6.244

10.  SLC35E3 identified as a target of novel‑m1061‑5p via microRNA profiling of patients with cardiovascular disease.

Authors:  Feng Gao; Fa-Gang Wang; Ren-Rong Lyu; Feng Xue; Jian Zhang; Ran Huo
Journal:  Mol Med Rep       Date:  2018-01-25       Impact factor: 2.952
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.